Multicenter Evaluation of the BD Phoenix CPO Detect Test for Detection and Classification of Carbapenemase-Producing Organisms in Clinical Isolates-Reference-Cited by-同舟云学术

Multicenter Evaluation of the BD Phoenix CPO Detect Test for Detection and Classification of Carbapenemase-Producing Organisms in Clinical Isolates

Published:2020-04-23 Issue:5 Volume:58 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Whitley Vicki¹,Kircher Susan¹,Gill Tracey¹,Hindler Janet A.²,O’Rourke Susan¹,Cooper Charles¹,Tulpule Anagha³,Denys Gerald A.³

Affiliation:

1. Becton, Dickinson and Company, BD Life Sciences-Integrated Diagnostic Solutions, Sparks, Maryland, USA

2. David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA

3. Indiana University School of Medicine, Indianapolis, Indiana, USA

Abstract

Limited treatment options contribute to high morbidity/mortality rates with carbapenem-resistant, Gram-negative bacterial infections. New approaches for carbapenemase-producing organism (CPO) detection may help inform clinician decision-making on patient treatment and infection control. BD Phoenix CPO detect (CPO detect) detects and classifies carbapenemases in Enterobacterales , Acinetobacter baumannii , and Pseudomonas aeruginosa during susceptibility testing.

Funder

Becton, Dickinson and Company

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01752-19

Reference45 articles.

1. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management

2. Risk for subsequent infection and mortality after hospitalization among patients with multidrug-resistant gram-negative bacteria colonization or infection

3. Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae